Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Nerinetide

Investigational

Neuroprotective PSD-95 inhibitor peptide

Also known as: NA-1, Tat-NR2B9c, Nerinetida, FN023, FN-023, nerinetidum

Evidence score

58/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 3 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Nerinetide, also called NA-1, is an investigational synthetic peptide studied as a possible neuroprotective treatment for acute ischemic stroke. It is designed to disrupt the interaction between the scaffolding protein PSD-95 and NMDA receptors, which is thought to reduce toxic nitric oxide signaling in nerve cells after loss of blood flow.

What the evidence shows

Automatic summaryLimited human data

Nerinetide is not FDA approved and has been tested in a small number of registered human trials reaching Phase 3, where overall results in stroke patients did not show a clear benefit, though some subgroup findings prompted further study. Whether it protects the brain in humans remains unproven.

Key facts

Molecular formula

C105H188N42O30

Molecular weight

2518.9 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

3registered studies

Phase 3most advanced phase

3completed (sample)

0recruiting (sample)

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

Phase 3CompletedNCT02315443

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Phase 3CompletedNCT02930018

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Phase 3CompletedNCT04462536

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

75papers referencing Nerinetide

Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.

Lancet2020

Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era.

Nat Rev Neurol2022

The future of neuroprotection in stroke.

J Neurol Neurosurg Psychiatry2021

PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides.

Int J Mol Sci2021

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.